Sanofi is betting $1.53 billion on a novel drug from Sino Biopharmaceutical, securing global rights to a first-in-class JAK/ROCK inhibitor that could play a double role in the French pharma’s ...

Pharmaceutical company says this and similar lawsuits are “premised on junk science that conflicts with decades of independent, peer‑reviewed research.” ...

The MarketWatch News Department was not involved in the creation of this content.-- Cebranopadol is an investigational first-of-its kind dual NOP/MOP receptor (NMR) agonist which ...

Please take a moment to scroll through 51 years of Pharmacy class composites. Click on individual slides to view larger images. (Some year's composites were not available for viewing). The University ...

The Ministry of Health and Family Welfare has issued a notification introducing amendments to the Drugs Rules, 1945, reinforcing quality control and licensing requirements.The ...

NervGen Pharma Corp. (“NervGen” or the “Company”) (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury ...

Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced ...

SIOUX FALLS, S.D. (KELO) — The boys basketball regular season came to a close on Friday night for class ‘A’ and ‘B’, leading to the announcement of the region brackets. The region playoffs begin on ...

HLP004 is an investigational intramuscular deuterated serotonergic agonist designed to activate serotonin pathways believed to promote neuroplasticity. The program is being developed as a potential ...

In a fourth-quarter conference call, Insmed CEO Will Lewis admitted that it was “audacious” that his company would project sales of newly approved respiratory drug Brinsupri to reach $1 billion in ...

Gilead Sciences, Inc.’s GILD Cell Therapy franchise currently comprises Yescarta and Tecartus. Sales from this unit decreased 7% year over year to $1.8 billion (in 2025) due to ongoing competitive ...